Mavenclad (Cladribine) Patent Expiration, LOE Window & CMS Spending

Mavenclad (Cladribine) by Emd Serono: FDA Orange Book LOE 2041-09-10, 2 AB generics, $244.0M 2024 CMS Part D & Medicaid spend, and 42 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEmd Serono
FDA Application & PathwayN022561 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2041-09-10
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$244.0M
2024 Medicare Part D Spend$178.2M
2024 Medicaid Spend$65.8M
Reported Wholesale Price Change (CA SB 17)42 WAC filings (max 21.2% 2-yr change)